Cargando…

Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer

Epidermal growth factor receptor (EGFR) mutations are the molecular driver of a subset of non-small cell lung cancers (NSCLC); tumors that harbor these mutations are often dependent on sustained oncogene signaling for survival, a concept known as “oncogene addiction”. Inhibiting EGFR with tyrosine k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farnsworth, Dylan A., Chen, Yankuan T., de Rappard Yuswack, Georgia, Lockwood, William W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699920/ https://www.ncbi.nlm.nih.gov/pubmed/34944063 http://dx.doi.org/10.3390/cells10123553

Ejemplares similares

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
por: Farnsworth, Dylan A., et al.
Publicado: (2022)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
por: Schaufler, Diana, et al.
Publicado: (2021)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
por: Cheng, Hua, et al.
Publicado: (2011)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021)

Minimal residual disease in EGFR-mutant non-small-cell lung cancer
por: Bain, Nathan T., et al.
Publicado: (2022)

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
por: Tone, Mari, et al.
Publicado: (2023)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
por: Fan, Fushun, et al.
Publicado: (2020)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy
por: Yu, Li, et al.
Publicado: (2022)

EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
por: Selenz, Carolin, et al.
Publicado: (2022)

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
por: Saifon, Woraseth, et al.
Publicado: (2022)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
por: Cho, Jong Ho, et al.
Publicado: (2018)

Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer
por: Mi, J., et al.
Publicado: (2021)

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
por: Ricciuti, Biagio, et al.
Publicado: (2015)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Vaclova, Tereza, et al.
Publicado: (2021)

Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR‑TKI resistance in EGFR mutant non-small cell lung cancer
por: Chen, Junjie, et al.
Publicado: (2023)

The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
por: Zhong, Wen-Zhao, et al.
Publicado: (2017)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
por: Gen, Soei, et al.
Publicado: (2022)

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
por: Yan, Dan, et al.
Publicado: (2022)

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Eggermont, Carolien, et al.
Publicado: (2022)

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
por: Niederst, Matthew J., et al.
Publicado: (2015)

Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer
por: Murillo, Miguel M., et al.
Publicado: (2018)

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Yochum, Zachary A., et al.
Publicado: (2018)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
por: Santoni-Rugiu, Eric, et al.
Publicado: (2019)

Targeting USP13‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer
por: Giron, Philippe, et al.
Publicado: (2021)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Chen, et al.
Publicado: (2021)

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
por: Liu, Si-Yang Maggie, et al.
Publicado: (2023)

Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
por: Wang, Haiyang, et al.
Publicado: (2018)

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
por: Bulbul, Ajaz, et al.
Publicado: (2018)

EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis
por: Mitra, Devarati, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n33heskps2rehjmolfrrauvao1